Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop

Molecular Vision

Volumn 16, Issue , 2010, Pages 1629-1639

  Kern, T S ^a,b   Miller, C M ^a,c   Tang, J ^a   Du, Y ^a   Ball, S L ^b   Berti Matera, L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c ALCON RESEARCH LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; VASCULOTROPIN;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA RHYTHM; CELL LOSS; CONTROLLED STUDY; DARK ADAPTATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE DURATION; LEWIS RAT; LIGHT ADAPTATION; NONHUMAN; PAIN ASSESSMENT; PATHOGENESIS; PERICYTE; PERIPHERAL NERVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RETINA CAPILLARY; RETINA DEGENERATION; RETINA GANGLION CELL; SPRAGUE DAWLEY RAT; STRAIN DIFFERENCE; WISTAR RAT;

ANIMALS; CAPILLARIES; CELL COUNT; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; HYPERESTHESIA; INFLAMMATION MEDIATORS; PERIPHERAL NERVOUS SYSTEM; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RETINAL GANGLION CELLS;

EID: 77956976493     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46:1829-1839.
2. Rema M, Saravanan G, Deepa R, Mohan V. Familial clustering of diabetic retinopathy in South Indian Type 2 diabetic patients. Diabet Med 2002; 19:910-916.
3. Pyke DA, Tattersall RB. Diabetic retinopathy in identical twins. Diabetes 1973; 22:613-618.
4. Hamman RF, Franklin GA, Mayer EJ, Marshall SM, Marshall JA, Baxter J, Kahn LB. Microvascular complications of NIDDM in Hispanics and non-Hispanic whites. San Luis Valley Diabetes Study. Diabetes Care 1991; 14:655-664.
5. Kalter-Leibovici O, Van Dyk DJ, Leibovici L, Loya N, Erman A, Kremer I, Boner G, Rosenfeld JB, Karp M, Laron Z. Risk factors for development of diabetic nephropathy and retinopathy in Jewish IDDM patients. Diabetes 1991; 40:204-210.
6. Ko BC, Lam KS, Wat NM, Chung SS. An (A-C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 1995; 44:727-732.
7. Heesom AE, Hibberd ML, Millward A, Demaine AG. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 1997; 46:287-291.
8. Demaine A, Cross D, Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000; 41:4064-4068.
9. Shimizu H, Ohtani KI, Tsuchiya T, Sato N, Tanaka Y, Takahashi H, Uehara Y, Inukai T, Mori M. Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese Type 2 diabetic (T2DM) patients. Diabetes Nutr Metab 2000; 13:75-79.
10. Santos KG, Tschiedel B, Schneider J, Souto K, Roisenberg I. Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. Diabetes Res Clin Pract 2003; 61:133-136.
11. Wang Y, Ng MC, Lee SC, So WY, Tong PC, Cockram CS, Critchley JA, Chan JC. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003; 26:2410-2415.
12. Demaine AG. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications. Curr Med Chem 2003; 10:1389-1398.
13. Chung SS, Chung SK. Genetic analysis of aldose reductase in diabetic complications. Curr Med Chem 2003; 10:1375-1387.
14. Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay NK, Paul PG, Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic Genet 2003; 24:41-48.
15. Amano S, Yamagishi S, Koda Y, Tsuneoka M, Soejima M, Okamoto T, Inagaki Y, Yamada K, Kimura H. Polymorphisms of sorbitol dehydrogenase (SDH) gene and susceptibility to diabetic retinopathy. Med Hypotheses 2003; 60:550-551.
16. Sivenius K, Niskanen L, Voutilainen-Kaunisto R, Laakso M, Uusitupa M. Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes. Diabet Med 2004; 21:1325-1333.
17. Petrovic MG, Peterlin B, Hawlina M, Petrovic D. Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in Type 2 diabetes in Caucasians. J Diabetes Complications 2005; 19:70-73.
18. Globocnik-Petrovic M, Hawlina M, Peterlin B, Petrovic D. Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes. Ophthalmologica 2003; 217:219-224.
19. Nagi DK, Mansfield MW, Stickland MH, Grant PJ. Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM. Diabet Med 1995; 12:997-1001.
20. Fujisawa T, Ikegami H, Shen GQ, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Ueda H, Rakugi H, Higaki J. Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care 1995; 18:983-985.
21. Dornan TL, Ting A, McPherson CK, Peckar CO, Mann JI, Turner RC, Morris PJ. Genetic susceptibility to the development of retinopathy in insulin-dependent diabetics. Diabetes 1982; 31:226-231.
22. Agardh D, Gaur LK, Agardh E, Landin-Olsson M, Agardh DD, Lernmark A. HLA-DQB1*0201/0302 is associated with severe retinopathy in patients with IDDM. Diabetologia 1996; 39:1313-1317.
23. Cruickshanks KJ, Vadheim CM, Moss SE, Roth MP, Riley WJ, Maclaren NK, Langfield D, Sparkes RS, Klein R, Rotter JI. Genetic marker associations with proliferative retinopathy in persons diagnosed with diabetes before 30 yr of age. Diabetes 1992; 41:879-885.
24. Warpeha KM, Chakravarthy U. Molecular genetics of microvascular disease in diabetic retinopathy. Eye 2003; 17:305-311.
25. Zhang SX, Ma JX, Sima J, Chen Y, Hu MS, Ottlecz A, Lambrou GN. Genetic difference in susceptibility to the blood-retina barrier breakdown in diabetes and oxygen-induced retinopathy. Am J Pathol 2005; 166:313-321.
26. Gao G, Li Y, Fant J, Crosson CE, Becerra SP, Ma JX. Difference in ischemic regulation of vascular endothelial growth factor and pigment epithelium-derived factor in brown norway and sprague dawley rats contributing to different susceptibilities to retinal neovascularization. Diabetes 2002; 51:1218-1225.
27. Rogers MS, Rohan RM, Birsner AE, D'Amato RJ. Genetic loci that control vascular endothelial growth factor-induced angiogenesis. FASEB J 2003; 17:2112-2114.
28. Rogers MS, Rohan RM, Birsner AE, D'Amato RJ. Genetic loci that control the angiogenic response to basic fibroblast growth factor. FASEB J 2004; 18:1050-1059.
29. Kern TS. In vivo models of diabetic retinopathy. In: Duh EJ, editor. Diabetic Retinopathy. Totowa, New Jersey: Humana Press; 2008. p. 137-156.
30. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol 2008; 586:4401-4408.
31. Zheng L, Kern T. In vivo animal models of diabetic retinopathy. In: HP Hammes, M Porta, editors. Experimental Approaches to Diabetic Retinopathy. Basel: Karger; 2010. p. 42-60
32. Korstanje R, DiPetrillo K. Unraveling the genetics of chronic kidney disease using animal models. Am J Physiol Renal Physiol 2004; 287:F347-F352.
33. Zheng F, Striker GE, Esposito C, Lupia E, Striker LJ. Strain differences rather than hyperglycemia determine the severity of glomerulosclerosis in mice. Kidney Int 1998; 54:1999-2007.
34. Hammes H-P, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88:11555-11558.
35. Kern TS, Engerman RL. Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res 1994; 13:863-867.
36. Hammes HP, Ali SS, Uhlmann M, Weiss A, Federlin K, Geisen K, Brownlee M. Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia 1995; 38:269-273.
37. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996; 97:2883-2890.
38. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001; 50:1938-1942.
39. Kern TS, Tang J, Mizutani M, Kowluru RA, Nagaraj RH, Romeo G, Podesta F, Lorenzi M. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci 2000; 41:3972-3978.
40. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9:294-299.
41. Engerman RL, Kern TS. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 1993; 42:820-825.
42. Kern TS, Engerman RL. Pharmacologic inhibition of diabetic retinopathy: Aminoguanidine and aspirin. Diabetes 2001; 50:1636-1642.
43. Zheng L, Szabo C, Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004; 53:2960-2967.
44. Ball SL, Powers PA, Shin HS, Morgans CW, Peachey NS, Gregg RG. Role of the beta [2] subunit of voltage-dependent calcium channels in the retinal outer plexiform layer. Invest Ophthalmol Vis Sci 2002; 43:1595-1603.
45. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55-63.
46. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozotocindiabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996; 68:293-299.
47. Berti-Mattera LN, Kern TS, Siegel RE, Nemet I, Mitchell R. Sulfasalazine Blocks the Development of Tactile Allodynia in Experimentally Diabetic Rats. Diabetes 2008; 57:2801-2808.
48. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007; 2007:95103.
49. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 2008; 30:65-84.
50. van Wijngaarden P, Coster DJ, Brereton HM, Gibbins IL, Williams KA. Strain-dependent differences in oxygeninduced retinopathy in the inbred rat. Invest Ophthalmol Vis Sci 2005; 46:1445-1452.
51. Dull BJ, Gittes RF, Goldman P. Nitrate production and phagocyte activation: differences among Sprague-Dawley, Wistar-Furth and Lewis rats. Carcinogenesis 1988; 9:625-627.
52. Gesualdo L, Emancipator SN, Kesselheim C, Lamm ME. Glomerular hemodynamics and eicosanoid synthesis in a rat model of IgA nephropathy. Kidney Int 1992; 42:106-114.
53. Matsubara S, Nakata A, Kikuchi M, Kikkawa H, Ikezawa K, Naito K. Strain-related differences in Sephadex bead-induced airway hyperresponsiveness and inflammation in rats. Inflamm Res 1997; 46:299-305.
54. Brown RF, Jackson GD, Martin T, Westbrook RF. Bacterial lipopolysaccharides induce peripheral nerve disturbances in rats that mimic human immune-mediated polyneuropathies. Lab Anim Sci 1997; 47:354-361.
55. Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 1997; 377:443-464.
56. Lovell JA, Stuesse SL, Cruce WL, Crisp T. Strain differences in neuropathic hyperalgesia. Pharmacol Biochem Behav 2000; 65:141-144.
57. Banik RK, Sato J, Yajima H, Mizumura K. Differences between the Lewis and Sprague-Dawley rats in chronic inflammation induced norepinephrine sensitivity of cutaneous C-fiber nociceptors. Neurosci Lett 2001; 299:21-24.
58. Kaminsky O, Klenerova V, Stohr J, Sida P, Hynie S. Differences in the behaviour of Sprague-Dawley and Lewis rats during repeated passive avoidance procedure: effect of amphetamine. Pharmacol Res 2001; 44:117-122.
59. Shir Y, Zeltser R, Vatine JJ, Carmi G, Belfer I, Zangen A, Overstreet D, Raber P, Seltzer Z. Correlation of intact sensibility and neuropathic pain-related behaviors in eight inbred and outbred rat strains and selection lines. Pain 2001; 90:75-82.
60. Benoliel R, Eliav E, Tal M. Strain-dependent modification of neuropathic pain behaviour in the rat hindpaw by a priming painful trigeminal nerve injury. Pain 2002; 97:203-212.
61. Aizu Y, Oyanagi K, Hu J, Nakagawa H. Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin-diabetic rats. Neuropathology 2002; 22:161-170.
62. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102:783-791.
63. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, Kim M, Jamison JA, Bingaman DP. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007; 56:373-379.
64. Reiter CE, Sandirasegarane L, Wolpert EB, Klinger M, Simpson IA, Barber AJ, Antonetti DA, Kester M, Gardner TW. Characterization of insulin signaling in rat retina in vivo and ex vivo. Am J Physiol Endocrinol Metab 2003; 285:E763-E774.
65. Antonetti DA, Lieth E, Barber AJ, Gardner TW. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 1999; 14:240-248.
66. Boeri D, Maiello M, Lorenzi M. Increased prevalence of microthromboses in retinal capillaries of diabetic individuals. Diabetes 2001; 50:1432-1439.
67. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002; 86:363-365.
68. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Döhmen S, Adamis AP. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002; 16:438-440.
69. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002; 51:3499-3504.
70. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103:1820-1828.
71. Miyamoto K, Khosrof S, Bursell SE, Moromizato Y, Aiello LP, Ogura Y, Adamis AP. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000; 156:1733-1739.
72. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133:373-385.
73. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18:1450-1452.
74. Zheng L, Du Y, Miller C, Gubitosi-Klug RA, Ball S, Berkowitz BA, Kern TS. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 2007; 50:1987-1996.
75. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylatebased anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 2007; 56:337-345.
76. Gubitosi-Klug RA, Talahalli R, Du Y, Nadler JL, Kern TS. 5-Lipoxygenase, but not 12/15-Lipoxygenase, Contributes to Degeneration of Retinal Capillaries in a Mouse Model of Diabetic Retinopathy. Diabetes 2008; 57:1387-1393.
77. Du Y, Tang J, Li G, Berti-Mattera L, Lee CA, Bartkowski D, Gale D, Monahan J, Niesman MR, Alton G, Kern TS. Inhibition of p38 MAPK inhibits early stages of diabetic retinopathy and sensory nerve function. Invest Ophthalmol Vis Sci 2010; 51:2158-2164.
78. Calcutt NA. Potential mechanisms of neuropathic pain in diabetes. Int Rev Neurobiol 2002; 50:205-228.
79. Lembertas AV, Pérusse L, Chagnon YC, Fisler JS, Warden CH, Purcell-Huynh DA, Dionne FT, Gagnon J, Nadeau A, Lusis AJ, Bouchard C. Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on the human homologous region 20q. J Clin Invest 1997; 100:1240-1247.
80. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 1999; 21:76-83.
81. Max M, Shanker YG, Huang L, Rong M, Liu Z, Campagne F, Weinstein H, Damak S, Margolskee RF. Tas1r3, encoding a new candidate taste receptor, is allelic to the sweet responsiveness locus Sac. Nat Genet 2001; 28:58-63.
82. Lee SH, Girard S, Macina D, Busà M, Zafer A, Belouchi A, Gros P, Vidal SM. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet 2001; 28:42-45.
83. Korstanje R, Paigen B. From QTL to gene: the harvest begins. Nat Genet 2002; 31:235-236.
84. Singer JB, Hill AE, Nadeau JH, Lander ES. Mapping quantitative trait loci for anxiety in chromosome substitution strains of mice. Genetics 2005; 169:855-862.